BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/6/2021 2:31:17 AM | Browse: 226 | Download: 326
 |
Received |
|
2021-01-27 12:59 |
|
Peer-Review Started |
|
2021-01-27 13:06 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-02-25 06:14 |
|
Revised |
|
2021-03-05 23:38 |
|
Second Decision |
|
2021-04-13 12:02 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-04-13 18:10 |
|
Articles in Press |
|
2021-04-13 18:10 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-06-21 07:27 |
|
Typeset the Manuscript |
|
2021-06-28 00:51 |
|
Publish the Manuscript Online |
|
2021-07-06 02:31 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Impact of COVID-19 pandemic on inflammatory bowel disease patients: A review of current evidence
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Marko Kumric, Tina Ticinovic Kurir, Dinko Martinovic, Piero Marin Zivkovic and Josko Bozic |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Josko Bozic, MD, PhD, Associate Professor, Department of Pathophysiology, University of Split School of Medicine, Soltanska 2, Split 21000, Croatia. josko.bozic@mefst.hr |
| Key Words |
COVID-19; SARS-CoV-2; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis |
| Core Tip |
Coronavirus disease 2019 (COVID-19) is the biggest medical issue of the 21st century so far. Among gastroenterology-related community, it was recognized with regard to patients with inflammatory bowel disease (IBD), as those patients are prone to opportunistic infections owing to their immunosuppressive-based therapies. Hence, in this review we summarized currently available data and concluded that patients with IBD are not at higher risk for COVID-19 development, unless treated with 5-aminosalicylates, and that outcomes of the infected patients depend on their respective therapeutic modalities. Finally, we discussed the impact of COVID-19 pandemic and concomitantly increased health care burden on IBD-management. |
| Publish Date |
2021-07-06 02:31 |
| Citation |
Kumric M, Ticinovic Kurir T, Martinovic D, Zivkovic PM, Bozic J. Impact of COVID-19 pandemic on inflammatory bowel disease patients: A review of current evidence. World J Gastroenterol 2021; 27(25): 3748-3761 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i25/3748.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i25.3748 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
